SynthesisBrain and behavior2019
The rate of early neurological deterioration occurring after thrombolytic therapy: A meta-analysis.
Synthesis in Brain and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk factors for unexplained early neurological deterioration after intravenous thrombolysis: a meta-analysis.Neurosciences (Riyadh, Saudi Arabia) · 2025Pooled it
- The rate of early neurological deterioration occurring after thrombolytic therapy: A meta-analysis.Brain and behavior · 2019Pooled it
- Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial.BMC neurology · 2025 · on this mapTrial
- Trial
- Article
- Admission Inflammatory-Metabolic Biomarker Profiles and Outcome-Specific Prognostic Patterns After Endovascular Therapy for Acute Ischemic Stroke: A Multicenter Cohort Study.Journal of inflammation research · 2026Article
- Safety and efficacy of tirofiban after intravenous thrombolysis with urokinase in patients with acute ischemic stroke.Frontiers in neurology · 2025Article
- Early Neurological Deterioration following acute stroke: association with reperfusion therapies and National Institutes Of Health Stroke Scale score.Frontiers in stroke · 2025Article
- Elevated NT-proBNP predicts unfavorable outcomes in patients with acute ischemic stroke after thrombolytic therapy.BMC neurology · 2023Article
- Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study.Therapeutic advances in neurological disorders · 2023Article
- Human urinary kallidinogenase may improve the prognosis of acute stroke patients with early neurological deterioration.Brain and behavior · 2022Article
- A New Classification System for Postinterventional Cerebral Hyperdensity: The Influence on Hemorrhagic Transformation and Clinical Prognosis in Acute Stroke.Neural plasticity · 2021Article
- Early Neurological Deterioration Despite Recanalization in Basilar Artery Occlusion Treated by Endovascular Therapy.Frontiers in neurology · 2020Article
- Hemoglobin-albumin-lymphocyte-platelet score and early neurological deterioration in acute ischemic stroke: a single-center retrospective cohort study.Frontiers in neurologyArticle
- SDNN predicts 90-day disability after intravenous thrombolysis: autonomic dysfunction as a novel predictors in acute ischemic stroke.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta-analysis was conducted in the present study.
methodsThe relevant studies were identified by searching PubMed, EMBASE, and Cochrane Collaboration Database up to June 2018. The definition of END was prespecified according to the most commonly used definition: ≥4-point increase in National Institutes of Health Stroke Scale between admission and 24 hr. The meta-analysis was performed by using the STATA 12.
resultsEleven studies with a total of 3,539 subjects, including 373 patients with END and 3,166 patients without END, were collected. The pooled analysis showed that the rate of END occurring after thrombolytic therapy was about 11.0% (95% CI: 7.8%-14.3%). Subgroup analysis by continent showed that the rate of END occurring after thrombolytic therapy of patients in Asia (15.9%, 95% CI: 7.4%-24.5%) was higher than in Europe (7.6%, 95% CI: 4.9%-10.3%) and in North America (11.8%, 95% CI: 8.5%-15.0%). Subgroup analysis by onset to treatment time (OTT) displayed that the rate of END occurring after thrombolytic therapy was 5.4% (95% CI: 1.2%-9.5%), 15.6% (95% CI: 9.6%-21.5%), and 18.5% (95% CI: 11.2%-25.8%) for the patients whose OTT ≤120.0 min, from 120.1 to 179.9 min, from 180.0 to 270.0 min, respectively.
conclusionThe rate of END occurring after thrombolytic therapy is about 11.0%. This finding may provide a scientific reference for researchers to evaluate the efficacy and safety of thrombolytic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.